Capabilities & Products
Intelligence aligned to the decisions you face —
stage by stage.
LCN's services aren't organized around methodologies. They're organized around the questions pharma leaders actually need answered at each stage of development — from preclinical strategy through in-market defense.
The Integration Advantage
Four capabilities.
One triangulated answer.
CI firms sell monitoring. Research firms sell surveys. Strategy firms sell frameworks. Each gives you one dimension. LCN integrates all four — so every signal is corroborated across methods, every conclusion is stress-tested from multiple angles, and every recommendation arrives decision-ready.
Competitive Intelligence
Pipeline tracking, landscape scans, congress monitoring, competitor simulation. Continuous surveillance that anticipates movement before it happens.
Primary Research
Direct dialogue with KOLs, HCPs, payers, and patients. Qualitative IDIs, quantitative surveys, conjoint, message testing — designed to surface signals that matter.
Analytics & Forecasting
Market sizing, epidemiology, patient-based forecasts, scenario modeling. Real-world dynamics, not optimistic assumptions.
Strategic Consulting
War gaming, scenario planning, launch readiness, portfolio prioritization. Decision support that translates evidence into action.
The Product Lifecycle
Jump to your stage.
Stage 01
Preclinical.
Where the bet begins.
Before clinical proof exists, decisions about target prioritization, modality choice, and pipeline investment shape what becomes possible later. The questions here are about scientific whitespace and long-horizon competitive landscape.
Key business questions at this stage:
- — Which targets and pathways are most differentiated relative to the global pipeline?
- — Where is the scientific and competitive whitespace we can credibly claim?
- — How large is the addressable opportunity if this works, and which indications maximize it?
Product
LandscapeDI
Comprehensive market landscape: pipeline, commercial brands, treatment algorithms, KOL perceptions, and whitespace. Triangulates digital intelligence with primary research.
Capability
Market Sizing & Epidemiology
Disease prevalence, eligible population modeling, and global geography of opportunity to assess the size of the prize before investment decisions are made.
Capability
Long-Range Scenario Planning
Explore alternative competitive and scientific futures to inform portfolio prioritization and target selection at the earliest possible point.
Stage 02
Phase 1.
Read the early signals — yours and theirs.
The first clinical signals from your asset arrive alongside competitor data. Trial design choices made here cascade into Phase 2 differentiation. BD&L decisions get made with imperfect data and big stakes.
Key business questions at this stage:
- — What are competitors signaling through their Phase 1 trial designs and early data?
- — Is this asset worth in-licensing, partnering, or accelerating — and what does the BD&L math actually look like?
- — Which KOLs should we be cultivating now, and which investigators should anchor our trials?
Product
LandscapeDI
Pipeline benchmarking, competitor trial design intelligence, and KOL perspectives on the emerging therapeutic category.
Product
MedConDI
Medical congress intelligence: capture competitor positioning, KOL perception, and non-public domain signals as competitor data is released.
Capability
Due Diligence & BD&L Support
Asset evaluation for in-licensing, M&A, and co-promotion decisions. Forecast the value, stress-test the strategic fit.
Stage 03
Phase 2 → Phase 3.
From "can this work" to "can this win."
The asset has proof of concept. Now the question is whether it can win — and the Phase 3 design has to prove it. Billions in investment, the competitive narrative, and what launch will look like all get locked in here, three to five years ahead of market entry.
Key business questions at this stage:
- — Where do we actually stand against competitors entering Phase 3 alongside us?
- — What story will we tell, to whom, and why will they care more about us than the alternatives?
- — How big is the opportunity, and can we defend a $500M+ Phase 3 commitment to the board?
Product
LandscapeDI
Full competitive landscape and KOL perception baseline — the foundation for every downstream Phase 3 decision.
Product
PositionDI
TPP stress-testing, whitespace mapping, and positioning hypothesis validation before Phase 3 design is locked. Know the winning story before you build the trial to prove it.
Product
MedConDI
Real-time competitor Phase 2 data readout monitoring at major scientific congresses. The intelligence the room gives you — before competitors act on it.
Capability
Forecasting & Scenario Modeling
Patient-based forecasting, market sizing, sensitivity analysis. Defend the Phase 3 investment case with evidence, not assumptions.
Capability
Phase 3 Readiness War Game
Stress-test the trial strategy against competitor moves. Pressure-test endpoints, indication strategy, and the commercial narrative before commitment.
Stage 04
Phase 3 in-flight → submission.
Build the market while the trial runs.
Most companies treat this stage as a waiting room. The companies that win at launch use every month of Phase 3 to build the commercial, medical, and access infrastructure that determines whether Day 1 is a success or a scramble.
Key business questions at this stage:
- — Has the competitive landscape shifted since Phase 3 began — and what do we do about it?
- — Have we built HCP segmentation, payer architecture, and brand pre-positioning before the data arrives?
- — Is the scientific narrative being shaped by KOLs aligned to us, or to competitors?
Product · Retainer
MarketWatchDI
Continuous competitive monitoring with rapid-alert and quarterly synthesis. Your competitors move continuously — your intelligence should too.
Product
LaunchFoundationDI
HCP segmentation, payer landscape, brand pre-positioning, and HEOR evidence roadmap. Build the commercial engine before the data gives you permission.
Product
NarrativeDI
KOL mapping, publication strategy, advisory board architecture, and pre-submission scientific narrative. Shape the conversation before your data shapes it for you.
Product
MedConDI
Congress execution layer — primary KOL intelligence and competitive narrative monitoring as data emerges in the public domain.
Stage 05
Pre-Launch.
Sharpen the message. Size the field.
Data has arrived. The label is taking shape. Now the work shifts to translating evidence into commercial execution: messaging that lands, sales force sized to the opportunity, channel mix that reaches the right prescribers, and a launch plan that survives competitive pressure.
Key business questions at this stage:
- — Which messages resonate with HCPs, payers, and patients — and which are table stakes vs. true differentiators?
- — How big should the field force be, and how do we deploy it against the highest-value prescribers?
- — What competitive moves should we plan for, and how do we sequence launch decisions to stay ahead?
Product
Field-ForceDI
Competitive field-force assessment: sizing, structure, call targeting, MSL deployment, and behavior. Confirmatory, non-public intelligence behind the enemy lines.
Capability
Message Testing & Concept Validation
Conjoint, MaxDiff, and concept testing across HCP, payer, and patient audiences to lock the messages that actually drive prescribing.
Capability
Launch Scenario Planning
War gaming competitive responses, sequencing decisions, and stress-testing the go-to-market plan before launch commitment is irreversible.
Stage 06
In-Market.
Defend share. Find the next move.
Launch is the beginning, not the finish line. Competitors respond, new entrants emerge, the payer environment shifts, and lifecycle decisions about indication expansion and lifecycle defense have to be made with the brand actively in the market.
Key business questions at this stage:
- — Where is share moving, why, and what's the appropriate defensive response?
- — What lifecycle moves — new indications, formulations, combinations — should we prioritize?
- — How do we sustain advantage as competitors launch and patents progress toward expiry?
Product · Retainer
MarketWatchDI
Continuous in-market monitoring across competitors, regulatory, access, and KOL channels with rapid alerts on material events.
Product
MedConDI
Ongoing congress intelligence — track competitor data, KOL sentiment shifts, and emerging narrative changes in real time.
Capability
Lifecycle Strategy
Indication expansion prioritization, formulation strategy, and lifecycle defense planning grounded in competitive and market intelligence.
Why a Single Firm Can Own This
The questions don't come in silos. Neither does the answer.
Every product in the LCN portfolio requires more than one capability at the same time. That's why no single-capability competitor can replicate it.
CI-Only Firms
Can monitor the competitive landscape. Cannot tell you what HCPs are thinking, how payers are positioned, or whether the message will land.
Qual MR Houses
Can run the HCP segmentation and the message testing. Have no CI capability to triangulate the signal against the competitive landscape.
Strategy Consultancies
Can write the narrative and frame the decision. Cannot field the primary research or sustain the continuous CI cadence to validate it.
LCN delivers all four — under one operating system, governed by a single process, accountable for a single answer.
Start a Conversation
Tell us where you are.
We'll tell you what the answer requires.
Every engagement begins with the business decision, not the methodology. Share the question on your desk — we'll come back with the right combination of CI, research, analytics, and strategy to answer it defensibly.
Start a ConversationWe respond to every inquiry within one business day.